28 February 2007
Futura Medical Plc Launches DermaSys® as brand name for proprietary drug delivery technology
Futura Medical plc (Futura), the AIM-listed pharmaceutical group that develops innovative products for the consumer healthcare market, announces the launch of DermaSys® as the brand name for its versatile gel technology for the rapid delivery of drugs through the skin.
The DermaSys® technology was originally developed by Futura for use in the Company’s topical treatment for erectile dysfunction, MED2002. Futura is continuing its assessment program for DermaSys® against a wide range of generic drugs suited to topical delivery where substantial improvements in speed of absorption and permeability across the skin would result in attractive commercial opportunities. For more information please visit the Futura website by clicking on the following link: http://www.futuramedical.co.uk/content/products/delivery_technology.asp
DermaSys® is a versatile and bespoke technology which can be adapted to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects.
James Barder, Futura Medical’s Chief Executive, said: “We are pleased to announce the launch of DermaSys® as the brand name of our proprietary drug delivery technology. DermaSys® is an important asset within Futura and we intend to continue to exploit its potential.”
For any further information please contact:
Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.co.uk
www.futuramedical.co.uk
For any media enquiries please contact:
Buchanan Communications Limited
Mark Court
Rebecca Skye Dietrich
+44 (0) 20 7466 5000